西罗莫司对比泼尼松初始治疗标准风险急性GVHD的随机多中心试验:BMT CTN 1501
本研究为多中心开放标签随机2期试验,纳入127例按Minnesota评分和Ann Arbor生物标志物定义的标准风险急性GVHD患者,比较西罗莫司与泼尼松初始治疗的28天完全/部分缓解率。结果显示两组28天CR/PR率相似(64.8% vs 73%),西罗莫司组泼尼松≤0.25 mg/kg/day时CR/PR率显著更高(66.7% vs 31.7%,P<.001),且减少激素暴露和高血糖、降低2-3级感染、改善免疫抑制停药和生活质量,但增加血栓性微血管病风险。
要点
- 标准风险急性GVHD患者中西罗莫司与泼尼松初始治疗28天缓解率相似。
- 西罗莫司组泼尼松≤0.25 mg/kg/day时28天CR/PR率显著高于泼尼松组。
- 西罗莫司减少激素暴露和高血糖、降低感染、改善生活质量,但增加血栓性微血管病风险。
核心结论
- 对于临床和生物标志物定义的标准风险急性GVHD患者,西罗莫司与泼尼松的总体初始治疗疗效相似。
- 西罗莫司治疗可减少激素暴露及相关毒性,不损害长期生存结局,并改善患者报告的生活质量。
研究设计与样本
- 由美国国家心肺血液研究所/国家癌症研究所资助的血液与骨髓移植临床试验网络开展的多中心、开放标签、随机2期试验。
- 共127例Minnesota标准风险患者随机1:1分组,其中122例为Ann Arbor AA1/2(西罗莫司n=58,泼尼松n=64),另4例AA3、1例AA状态缺失。
主要发现
- 第28天CR/PR率西罗莫司组为64.8%(90%CI 54.1%-75.5%),泼尼松组为73%(90%CI 63.8%-82.2%)。
- 泼尼松≤0.25 mg/kg/day时第28天CR/PR率西罗莫司组显著高于泼尼松组(66.7% vs 31.7%;P<.001)。
- 两组在激素难治性急性GVHD、无病生存、复发、非复发死亡或总生存方面未检测到差异。
- 西罗莫司与减少激素暴露和高血糖、降低2-3级感染、改善免疫抑制停药及患者报告生活质量相关,但增加血栓性微血管病风险。
关键数值与推荐
- 标准风险定义基于Minnesota GVHD风险评分和Ann Arbor生物标志物状态(AA1/2)。
- 主要终点为第28天完全缓解/部分缓解率。
临床怎么用
- 西罗莫司可作为标准风险急性GVHD的初始治疗选择,疗效与泼尼松相当且减少激素暴露。
- 使用西罗莫司时需注意监测血栓性微血管病风险。
局限性
- 本研究为2期试验,样本量有限(127例随机),部分患者AA状态缺失。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical- and biomarker-based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced-intensity treatments. Previous data suggest sirolimus may rival standard of care prednisone. We conducted a National Heart, Lung, and Blood Institute/National Cancer Institute-funded Blood and Marrow Transplant Clinical Trials Network multicenter, open-label, randomized phase 2 trial to estimate the difference in day 28 complete response (CR)/partial response (PR) rates for sirolimus vs prednisone as initial treatment of patients with standard risk (SR) acute GVHD as defined by the Minnesota (MN) GVHD Risk Score and Ann Arbor (AA1/2) biomarker status. A total of 127 MN-SR patients were randomized (1:1), and 122 were AA1/2 (sirolimus, n = 58; prednisone, n = 64). Others were AA3 (n = 4), or AA status missing (n = 1). The day 28 CR/PR rates were similar for sirolimus 64.8% (90% confidence interval [CI], 54.1%-75.5%) vs 73% (90% CI, 63.8%-82.2%) for prednisone. The day 28 rate of CR/PR with prednisone ≤0.25 mg/kg/day was significantly higher for sirolimus than prednisone (66.7% vs 31.7%; P < .001). No differences were detected in steroid-refractory acute GVHD, disease-free survival, relapse, nonrelapse mortality, or overall survival. Sirolimus was associated with reduced steroid exposure and hyperglycemia, reduced grade 2 to 3 infections, improvement in immune suppression discontinuation and patient-reported quality of life, and increased risk for thrombotic microangiopathy. For patients with clinical- and biomarker-based SR acute GVHD, sirolimus demonstrates similar overall initial treatment efficacy as prednisone. In addition, sirolimus therapy spares steroid exposure and allied toxicity, does not compromise long-term survival outcomes, and is associated with improved patient-reported quality of life. This trial was registered at www.clinicaltrials.gov as #NCT02806947.
引用
- Pidala J, Hamadani M, Dawson P, et al. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood. 2020. PMID: 31738834. doi:10.1182/blood.2019003125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。